THE SUCCESSFUL EXPERIENCE OF ANTIVIRAL THERAPY FOR HEPATITIS C IN PATIENTS WITH HEPATOCELLULAR CARCINOMA IN THE EARLY POSTOPERATIVE PERIOD

Abstract

To show the need for a comprehensive assessment of non-invasive, invasive and laboratory examination of patients with newly diagnosed hepatitis, especially in presence of space-occupying lesions of the liver (cysts) for detection of cancer pathology. Methods of performing. To confirm the diagnosis of HCC, the following instrumental methods of examination of the patient have been performed: ultrasound, CT and MRI of the internal organs of the pelvis and abdomen. The puncture of cystic formation was performed with the purpose of morphological verification of the diagnosis. A morphological and histological study of the tumor was performed. Evaluation of laboratory parameters included the basic general clinical and biochemical analyzes, as well as FibroMax, tumor markers: CEA, SA19-9, AFR, the qualitative and quantitative determination of HCV RNA. Results. Showed that taken separately laboratory values or single screening tool examination fail to give the fully valid answer about the nature and course of the pathological process. Conclusion. Comprehensive evaluation of patients with newly diagnosed HCV and timely initiated antiviral therapy permit to prevent or postpone the promote manifestations of chronic HCV, to preclude the development of primary HCC and its recurrence. When making a decision on the tactics of the management of the patient it is necessary to consider the totality of all the necessary instrumental and non-instrumental and laboratory methods of examination Keywords: chronic viral hepatitises C, hepatocellular carcinoma, oncomarkers, treatment of HCC and CHCV

References

[1] Абдурахманов Д.Т. Перспективы в лечении хронического вирусного гепатита C. Клин.гепатология, 2010, 3, 3-11.

[2] Craxi A. Клинические рекомендации ЕАSL ведение больных с инфекцией вызванной вирусом гепатита C. Best clinical practice. Рус. изд. 2011. 5. 13-37.

[3] Ghany M.G., Stader D.B., Thomas D.L., Seeff L.B. Diagnosis, management and treatment of hepatitis C: an update. Hepatology 2009: 49: 1335-1374.

[4] Жданов К., Лобзин Ю.В., Гусев Д.А., Козлов К.В. Вирусные гепатиты. - СПб.: Фолиант; 2012.

[5] Bacon Br. R., O'Grady J. G., Di Bisceglie A. M., Lake J. R. Clinical he-patology. Elsevier MOSBY; 2006.

[6] El-Serag H.B., Rudoiph R.L. Hepatocellular carcinoma: epidemiology and molecular cancirogenesis. Gastroenterology 2007; 132: 2557-2576.

[7] Marcellin P., Assellah T., Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36 (Suppl 1): 47-56.

[8] Alberti A. Impact of sustained virological response on the long-term outcome of hepatitis C. Liver Int. 2011, 31 (Suppl. 1): 18-22.

[9] Kirk G.D., Lesi O.A., Mendy M. et al. The Gambia Liver Cancer Study: infection with hepatitis and Cand the riskof hepatocellularcarcinoma in West Africa. Hepatology 2004, 39: 211-219.

[10] Серов В.В., Апросина З.Г. Хронический вирусный гепатит. - М.: Медицина, 2002.

[11] Adinolfi L.E., Utili R., Andreana A. et al. Serum HCV RNA levels corralate with histological liver damage and concur with steatosis in progression of chronic hepatitis C. Dig. Dis. Sci, 2001; 46: 1677-1683.

[12] Rubbia-Brandt L., Quardi R., Abid K. et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. Hepatology, 2000, 33: 106-115.

[13] Cardoso A.C., Moucari R., Figueredo-Mendes C. et al. Impact peginterferon and ribaverin therapyon hepatocellular carcinoma: incidence and survival in hepatits C pacients with advanced fibrosis. Hepatology 2010; 52: 652-65.

RIGHTS & PERMISSIONS

Eco-vector